Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2176
First Interstate BancSystem
FIBK
$3.31B
| $2.04M | ﹤0.01% |
65,772
-170,409
| -72% | -$5.2M |
2013 Q2
28 quarters
|
|
|
SFE
2177
DELISTED
Safeguard Scientifics, Inc.
SFE
| $2.03M | ﹤0.01% |
289,417
-63,500
| -18% | -$402K |
2015 Q2
20 quarters
|
|
2178
MediWound
MDWD
$158M
| $2.02M | ﹤0.01% |
97,075
+30,607
| +46% | +$436K |
2015 Q2
20 quarters
|
|
2179
UTStarcom
UTSI
$22.6M
| $2.02M | ﹤0.01% |
287,999
+3,292
| +1% | +$24.4K |
2013 Q2
28 quarters
|
|
2180
iShares Russell Mid-Cap ETF
IWR
$56.6B
| $2.02M | ﹤0.01% |
37,600
+32,800
| +683% | +$1.64M |
2020 Q1
1 quarter
|
|
2181
Protalix BioTherapeutics
PLX
$222M
| $2.01M | ﹤0.01% |
530,434
+53,000
| +11% | +$181K |
2015 Q4
18 quarters
|
|
2182
The Ensign Group
ENSG
$10.1B
| $2.01M | ﹤0.01% |
+48,000
| New | +$1.9M |
2020 Q2
0 quarters
|
|
2183
Patrick Industries
PATK
$2.07B
| $2.01M | ﹤0.01% |
+49,203
| New | +$1.49M |
2020 Q2
0 quarters
|
|
2184
DELISTED
CAMBRIDGE BANCORP
CATC
| $2.01M | ﹤0.01% |
33,873
+990
| +3% | +$52.1K |
2018 Q3
7 quarters
|
|
|
JAX
2185
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $2M | ﹤0.01% |
407,605
-10,900
| -3% | -$49.5K |
2016 Q2
16 quarters
|
|
|
GCP
2186
DELISTED
GCP Applied Technologies Inc.
GCP
| $2M | ﹤0.01% |
107,800
-14,100
| -12% | -$253K |
2019 Q1
5 quarters
|
|
2187
Vanguard Morningstar Mid-Cap ETF
VO
$107B
| $2M | ﹤0.01% |
48,800
+40,400
| +481% | +$1.55M |
2020 Q1
1 quarter
|
|
|
NSTG
2188
DELISTED
NanoString Technologies, Inc.
NSTG
| $2M | ﹤0.01% |
+68,100
| New | +$2.03M |
2020 Q2
0 quarters
|
|
2189
Cumberland Pharmaceuticals
CPIX
$107M
| $2M | ﹤0.01% |
599,458
+127,800
| +27% | +$465K |
2013 Q2
28 quarters
|
|
2190
Cheetah Mobile
CMCM
$78.2M
| $1.99M | ﹤0.01% |
231,785
-25,774
| -10% | -$303K |
2018 Q4
6 quarters
|
|
2191
DELISTED
Affimed
AFMD
| $1.98M | ﹤0.01% |
42,960
+4,760
| +12% | +$132K |
2020 Q1
1 quarter
|
|
2192
Ladder Capital
LADR
$1.11B
| $1.97M | ﹤0.01% |
243,241
-834,500
| -77% | -$6.26M |
2018 Q1
9 quarters
|
|
2193
Penske Automotive Group
PAG
$12.8B
| $1.97M | ﹤0.01% |
+50,800
| New | +$1.77M |
2020 Q2
0 quarters
|
|
|
ASPU
2194
DELISTED
ASPEN GROUP, INC.
ASPU
| $1.96M | ﹤0.01% |
216,967
+133,300
| +159% | +$1.1M |
2019 Q4
2 quarters
|
|
2195
Axcelis
ACLS
$3.86B
| $1.96M | ﹤0.01% |
+70,499
| New | +$1.72M |
2020 Q2
0 quarters
|
|
2196
nVent Electric
NVT
$26.1B
| $1.96M | ﹤0.01% |
+104,441
| New | +$1.9M |
2020 Q2
0 quarters
|
|
2197
Ranpak Holdings
PACK
$303M
| $1.95M | ﹤0.01% |
+262,457
| New | +$1.93M |
2020 Q2
0 quarters
|
|
2198
Century Aluminum
CENX
$3.38B
| $1.95M | ﹤0.01% |
+273,555
| New | +$1.45M |
2020 Q2
0 quarters
|
|
2199
Beazer Homes USA
BZH
$892M
| $1.95M | ﹤0.01% |
193,560
-106,300
| -35% | -$850K |
2018 Q3
7 quarters
|
|
2200
Gulf Resources
GURE
$5.06M
| $1.94M | ﹤0.01% |
36,261
+34
| +0.1% | +$1.54K |
2013 Q2
28 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.